Update
$Coherus BioSciences(CHRS.US$ Coherus Presents Preliminary Results From Phase I Dose Escalation Study of Its Anti-Chemokine Receptor 8 (Ccr8) Antibody, Chs-114, at the 2024 American Society of Clinical Oncology (Asco) Annual Meeting
Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors
Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
买跌不追涨 : This news feels average
TrytosaveabitOP 买跌不追涨: As far as compared to other BIO news! You are correct